StockNow
Log in
Global Markets

Abivax (ABVX FP) CEO says the latest funding round has permitted a move towards launching its bowel disease drug in the US without requiring 3rd party support, CNBC

StockNow breaking-news AI analysis

Abivax's $920M capital raise funds an independent US launch of its "best-in-disease" drug, obefazimod, through 2029, positioning it as a strong competitor amidst persistent M&A speculation.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement